Updated Analysis Show Seagen's Tukysa Extended Median OS to Two Years with Benefits Maintained in Breast Cancer

Seagen Inc SGEN has announced that improvements in overall survival (OS) and progression-free survival (PFS) were maintained with long-term follow-up from the HER2CLIMB trial of Tukysa (tucatinib) in metastatic breast cancer (MBC).
The trial evaluated the addition of Tukysa to trastuzumab and capecitabine in patients with HER2-positive MBC with and without brain metastases.
Data will be presented at the 2021 American Society of Clinical Oncology Annual Meeting.
The overall survival benefit seen with Tukysa at the primary analysis time was maintained after an additional 15.6 months of follow-up, demonstrating a 5.5-month improvement in median OS to 24.7 months for the Tukysa regimen vs. 19.2 months for capecitabine and trastuzumab alone.
The median progression-free survival in the Tukysa arm was 7.6 months, compared to the median PFS of 4.9 months in the control arm.
The safety profile was generally consistent with the primary analysis.
Related content: Benzinga's Full FDA Calendar.
Price Action: SGEN shares closed at $148.16 on Wednesday.